|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
|
AU2005263994B2
(en)
|
2004-07-22 |
2011-03-24 |
Roger Kingdon Craig |
Binding molecules
|
|
CA2638117A1
(en)
*
|
2006-01-25 |
2007-08-30 |
Erasmus University Medical Center Rotterdam |
Generation of heavy-chain only antibodies in transgenic animals
|
|
GB0601511D0
(en)
*
|
2006-01-25 |
2006-03-08 |
Univ Erasmus Medical Ct |
Binding Molecules 2
|
|
GB0618345D0
(en)
*
|
2006-09-18 |
2006-10-25 |
Univ Erasmus |
Binding molecules
|
|
EP2557090A3
(en)
|
2006-12-19 |
2013-05-29 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
EP2514767A1
(en)
|
2006-12-19 |
2012-10-24 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
|
GB0706628D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Univ Erasmus |
Germ-line manipulation 1
|
|
EP3382022A1
(en)
|
2007-06-01 |
2018-10-03 |
Open Monoclonal Technology, Inc. |
Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
|
|
AU2008328781A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
|
|
WO2009121948A2
(en)
|
2008-04-03 |
2009-10-08 |
Vib Vzw |
Single domain antibodies capable of modulating bace activity
|
|
US9908943B2
(en)
|
2008-04-03 |
2018-03-06 |
Vib Vzw |
Single domain antibodies capable of modulating BACE activity
|
|
CN102056945A
(en)
|
2008-04-07 |
2011-05-11 |
埃博灵克斯股份有限公司 |
Amino acid sequences directed against the Notch pathways and uses thereof
|
|
BRPI0911984A2
(en)
|
2008-05-16 |
2016-09-20 |
Ablynx Nv |
amino acid sequences directed against cxcr4 and other gpcrs compounds comprising the same
|
|
AU2009248834B2
(en)
*
|
2008-05-23 |
2014-10-30 |
Ablexis Llc |
Method of generating single VL domain antibodies in transgenic animals
|
|
JP5809557B2
(en)
|
2008-06-05 |
2015-11-11 |
アブリンクス エン．ヴェー． |
Amino acid sequences directed against viral envelope proteins and polypeptides containing them for the treatment of viral diseases
|
|
US20110314563A1
(en)
*
|
2008-12-18 |
2011-12-22 |
Kingdon Craig R |
Antibody production
|
|
HUE042919T2
(en)
|
2008-12-19 |
2019-07-29 |
Ablynx Nv |
Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
|
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
|
ES2894364T3
(en)
|
2009-10-22 |
2022-02-14 |
Univ Twente |
VHH for application in tissue repair, organ regeneration, organ replacement, and tissue engineering
|
|
JP5909449B2
(en)
|
2009-12-10 |
2016-04-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Mice producing heavy chain antibodies
|
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
|
PL2505654T5
(en)
|
2010-02-08 |
2020-11-30 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
WO2011117423A1
(en)
|
2010-03-26 |
2011-09-29 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
GB201014715D0
(en)
|
2010-09-06 |
2010-10-20 |
Vib Vzw |
Nanobodies stabilizing functional conformational states of GPCRS
|
|
NZ707327A
(en)
|
2010-08-02 |
2017-01-27 |
Regeneron Pharma |
Mice that make binding proteins comprising vl domains
|
|
ES2634547T3
(en)
|
2010-08-26 |
2017-09-28 |
Agrosavfe N.V. |
Compositions for seed treatment
|
|
CU24111B1
(en)
|
2010-11-08 |
2015-08-27 |
Novartis Ag |
POLYPEPTIDES THAT LINK TO CXCR2
|
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
|
JP6181040B2
(en)
|
2011-03-28 |
2017-08-16 |
アブリンクス エン．ヴェー． |
Bispecific anti-CXCR7 immunoglobulin single variable domain
|
|
UA117218C2
(en)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
|
|
CN107857810A
(en)
|
2011-06-21 |
2018-03-30 |
非营利性组织佛兰芒综合大学生物技术研究所 |
For GPCR:The binding structural domain of G-protein compound and the purposes from it
|
|
WO2013022782A1
(en)
|
2011-08-05 |
2013-02-14 |
Regeneron Pharmaceuticals, Inc. |
Humanized universal light chain mice
|
|
LT2627773T
(en)
|
2011-10-17 |
2017-12-27 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
|
KR102038974B1
(en)
|
2011-12-20 |
2019-10-31 |
리제너론 파마슈티칼스 인코포레이티드 |
Humanized light chain mice
|
|
EP2617732A1
(en)
|
2012-01-19 |
2013-07-24 |
Vib Vzw |
Tools and methods for expression of membrane proteins
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
JP6411333B2
(en)
|
2012-05-24 |
2018-10-24 |
ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ |
Anti-macrophage mannose receptor single variable domain for tumor-associated macrophage targeting and INVIVO imaging
|
|
PL2858487T3
(en)
|
2012-06-12 |
2020-06-01 |
Regeneron Pharmaceuticals, Inc. |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
|
WO2014118297A1
(en)
|
2013-01-30 |
2014-08-07 |
Vib Vzw |
Novel chimeric polypeptides for screening and drug discovery purposes
|
|
EP2953973B1
(en)
|
2013-02-05 |
2019-07-10 |
VIB vzw |
Muscarinic acetylcholine receptor binding agents and uses thereof
|
|
DK2840892T3
(en)
|
2013-02-20 |
2018-07-23 |
Regeneron Pharma |
Non-human animals with modified heavy chain immunoglobulin sequences
|
|
WO2014141192A1
(en)
|
2013-03-15 |
2014-09-18 |
Erasmus University Medical Center |
Generation of heavy chain-only antibodies
|
|
JP6499090B2
(en)
|
2013-03-15 |
2019-04-10 |
ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ |
Anti-macrophage mannose receptor single variable domain for use in cardiovascular disease
|
|
JP6687525B2
(en)
|
2014-01-30 |
2020-04-22 |
ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ |
Opioid receptor binding agents and uses thereof
|
|
KR102846903B1
(en)
|
2014-03-21 |
2025-08-20 |
리제너론 파마슈티칼스 인코포레이티드 |
Non-human animals that make single domain binding proteins
|
|
US20150266976A1
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
BR112017024899A2
(en)
|
2015-05-21 |
2018-11-13 |
Harpoon Therapeutics, Inc. |
trispecific binding proteins and methods of use.
|
|
CN105384825B
(en)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
|
|
JP7030704B2
(en)
|
2016-02-05 |
2022-03-08 |
オリオニス バイオサイエンシズ ビーブイ |
Bispecific signaling substances and their use
|
|
CN109069573B
(en)
|
2016-03-07 |
2022-04-05 |
弗拉芒区生物技术研究所 |
Single domain antibody that binds CD20
|
|
WO2017158436A1
(en)
|
2016-03-17 |
2017-09-21 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
CN109563141A
(en)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
To the therapeutic targeting of cellular structures
|
|
BR112018073761A2
(en)
|
2016-05-20 |
2019-02-26 |
Harpoon Therapeutics, Inc. |
single chain variable fragment cd3 binding proteins
|
|
JP7101621B2
(en)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
Single domain serum albumin binding protein
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
KR20190087539A
(en)
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
PSMA-targeted triple specific proteins and methods of use
|
|
WO2018098354A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
CA3050715A1
(en)
|
2017-01-19 |
2018-07-26 |
Open Monoclonal Technology, Inc. |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
EP3577133A1
(en)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Targeted chimeric proteins and uses thereof
|
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
|
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
CA3063359A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
WO2018222587A1
(en)
|
2017-05-30 |
2018-12-06 |
The Regents Of The University Of California |
NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric antibody immune effctor cell engagers and methods of use thereof
|
|
KR102425983B1
(en)
|
2017-10-13 |
2022-07-29 |
하푼 테라퓨틱스, 인크. |
Trispecific Proteins and Methods of Use
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B cell maturation antigen binding proteins
|
|
AU2018396964C1
(en)
|
2017-12-28 |
2024-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against PD-L1
|
|
SG11202004158QA
(en)
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
CN111699200B
(en)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
Single domain antibodies against PD-1 and variants thereof
|
|
EP3743448A4
(en)
|
2018-01-26 |
2021-11-03 |
Orionis Biosciences, Inc. |
XCR1 LINKERS AND THEIR USES
|
|
EP3749295A4
(en)
|
2018-02-05 |
2022-04-27 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
EP3774917B1
(en)
|
2018-03-30 |
2025-10-29 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
|
BR112020023330A2
(en)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
binding portion for conditional activation of immunoglobulin molecules
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
CN117442717A
(en)
|
2018-06-01 |
2024-01-26 |
大有华夏生物医药集团有限公司 |
Compositions for treating diseases or conditions and uses thereof
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
TWI841595B
(en)
|
2018-09-10 |
2024-05-11 |
大陸商南京傳奇生物科技有限公司 |
Single-domain antibodies against cd33 and constructs thereof
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3856771A4
(en)
|
2018-09-25 |
2022-06-29 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
CN113795511B
(en)
|
2019-01-23 |
2024-07-23 |
大有华夏生物医药集团有限公司 |
Anti-PD-L1 double antibody and its use
|
|
KR20220008866A
(en)
|
2019-05-14 |
2022-01-21 |
하푼 테라퓨틱스, 인크. |
EpCAM binding proteins and methods of use
|
|
CN110818795B
(en)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
anti-TIGIT antibodies and methods of use
|
|
KR20220144841A
(en)
|
2020-02-21 |
2022-10-27 |
하푼 테라퓨틱스, 인크. |
FLT3 Binding Proteins and Methods of Use
|
|
WO2021170067A1
(en)
|
2020-02-28 |
2021-09-02 |
上海复宏汉霖生物技术股份有限公司 |
Anti-cd137 construct and use thereof
|
|
CN115151573A
(en)
|
2020-02-28 |
2022-10-04 |
上海复宏汉霖生物技术股份有限公司 |
anti-CD 137 constructs, multispecific antibodies, and uses thereof
|
|
CN116529260A
(en)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
anti-CD 93 constructs and uses thereof
|
|
JP2023529842A
(en)
|
2020-06-02 |
2023-07-12 |
ダイナミキュア バイオテクノロジー エルエルシー |
Anti-CD93 constructs and uses thereof
|
|
IL298909A
(en)
|
2020-06-17 |
2023-02-01 |
Janssen Biotech Inc |
Materials and methods for the production of multipurpose stem cells
|
|
EP4188550A1
(en)
|
2020-07-29 |
2023-06-07 |
Dynamicure Biotechnology LLC |
Anti-cd93 constructs and uses thereof
|
|
MX2023001708A
(en)
|
2020-08-10 |
2023-05-04 |
Janssen Biotech Inc |
MATERIALS AND METHODS TO PRODUCE VIRUS-SPECIFIC LYMPHOCYTES DESIGNED THROUGH BIOENGINEERING.
|
|
CN118146382A
(en)
|
2020-09-28 |
2024-06-07 |
安济盛生物医药有限公司 |
Anti-sclerostin constructs and uses thereof
|
|
CN116723861A
(en)
|
2020-12-02 |
2023-09-08 |
上海复宏汉霖生物技术股份有限公司 |
Anti-GARP/TGFβ antibodies and how to use them
|
|
WO2022156908A1
(en)
|
2021-01-25 |
2022-07-28 |
Vrije Universiteit Brussel |
Method for preparing a lyophilized composition
|
|
WO2022157373A1
(en)
|
2021-01-25 |
2022-07-28 |
Vrije Universiteit Brussel |
Compositions and kits for in vivo imaging of cardiac sarcoidosis
|
|
WO2022156907A1
(en)
|
2021-01-25 |
2022-07-28 |
Vrije Universiteit Brussel |
Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
|
|
WO2022178255A2
(en)
|
2021-02-19 |
2022-08-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
|
BR112023016706A2
(en)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Antibody or an antigen-binding fragment thereof, nucleic acid molecule, methods for producing an antibody or an antigen-binding fragment thereof and for detecting cluster of differentiation 47 or determining an amount of cluster of differentiation 47 in a sample, and, use of the antibody or an antigen-binding fragment thereof
|
|
JP7773237B2
(en)
|
2021-02-19 |
2025-11-19 |
シャペロン インク． |
Single domain antibodies against CD47 and uses thereof
|
|
WO2022177394A1
(en)
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Bispecific single domain antibody to pd-l1 and cd47 and use thereof
|
|
CN117715933A
(en)
|
2021-03-05 |
2024-03-15 |
当康生物技术有限责任公司 |
Anti-VISTA constructs and their uses
|
|
CN117616041A
(en)
|
2021-03-25 |
2024-02-27 |
当康生物技术有限责任公司 |
Anti-IGFBP7 constructs and their uses
|
|
US12227574B2
(en)
|
2021-06-17 |
2025-02-18 |
Amberstone Biosciences, Inc. |
Anti-CD3 constructs and uses thereof
|
|
WO2022269473A1
(en)
|
2021-06-23 |
2022-12-29 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
EP4412663A1
(en)
|
2021-10-05 |
2024-08-14 |
Vrije Universiteit Brussel |
Fluorescently labeled immunoglobulin single variable domains
|
|
JP2024547020A
(en)
|
2021-12-17 |
2024-12-26 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
Anti-OX40 antibodies, multispecific antibodies and methods of use thereof
|
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
|
CN118974096A
(en)
|
2022-03-25 |
2024-11-15 |
上海复宏汉霖生物技术股份有限公司 |
Anti-MSLN antibodies and methods of use
|
|
EP4558151A1
(en)
|
2022-07-22 |
2025-05-28 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
|
JP2025531788A
(en)
|
2022-09-07 |
2025-09-25 |
ダイナミキュア バイオテクノロジー エルエルシー |
Anti-VISTA constructs and uses thereof
|
|
EP4349374A1
(en)
|
2022-10-05 |
2024-04-10 |
Vrije Universiteit Brussel |
Anti-urokinase plasminogen activator receptor immunoglobulin single variable domains
|
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
EP4512243A1
(en)
|
2023-08-21 |
2025-02-26 |
Kymab Limited |
Binding molecules
|
|
WO2025045251A2
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Multispecific constructs comprising anti-factor d moiety
|
|
WO2025088085A1
(en)
|
2023-10-26 |
2025-05-01 |
Abscint Nv |
Image guided biopsy of her2 positive lesions
|
|
WO2025178959A1
(en)
|
2024-02-20 |
2025-08-28 |
University Of Georgia Research Foundation, Inc. |
Single-domain antibodies and variants thereof against tab1
|